Two posters compared health care resource utilization (HCRU) and financial burdens of people living with HIV with a non-HIV population and people with HIV who are heavily treated with those have ...

Since its first approval in 2022, Gilead Sciences’ lenacapavir—a twice-yearly injectable—has come to be a potential game ...

Opinion: "While the obstacles we face may be significant, Lenacapavir represents a monumental breakthrough in the fight ...

A new HIV prevention drug will be made available at a lower cost in over 100 low-income countries within two years — a move expected to give millions access to the breakthrough treatment and ...

A little over two decades ago, addressing Nigeria’s HIV crisis topped U.S. President George W. Bush’s priorities. Africa’s most populous nation had 3.5 million HIV cases, and the disease threatened to ...

The 15 drugs accounted for $27bn in spending via Medicare Part B and Part D between November 2024 and October 2025.

Improved efforts to link and retain HIV-positive individuals in care, along with increased screening for HIV, could reduce the incidence of HIV infection and deaths from AIDS in the United States by ...

To quote Florida Surgeon General Joseph Ladapo, “It’s a really, really serious issue.” Here are the facts: More than 32,000 ...

The AIDS Healthcare Foundation, the world’s largest HIV/AIDS nonprofit organization, fled a petition in Tallahassee on ...

New guidelines update ART choices, endorse long-acting injectables, refine infant feeding advice, and prioritise shorter TB ...

After four decades of hard-won progress toward curbing the HIV epidemic, the face of the disease is changing.